Warren J. Strittmatter

Triangle — United States

Medicine · Health Sciences

57h-index33.2kcitations140works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(48), Genetic Neurodegenerative Diseases(25), Mitochondrial Function and Pathology(14), Nuclear Receptors and Signaling(10), Cholinesterase and Neurodegenerative Diseases(9)

Publications140 total

Phase 2 PIONEER Trial of Oral T3D‐959 for the Treatment of Patients Diagnosed with Mild‐to‐Moderate Alzheimer’s Disease: New Results in a Modified Intent‐to‐Treat Population
Alzheimer s & Dementia·2024· 1 citedOpen Access
Towards a more representative Alzheimer’s disease clinical trial: Ethnic differences in underlying pathology call for demographic consideration in drug label development
Alzheimer s & Dementia·2022
The PIONEER Study: A Multi‐center, Randomized, Double‐blind, Placebo‐controlled Phase 2 Trial of the Effects of T3D‐959 on Safety, Cognition, Function and Plasma Biomarkers in Mild to Moderate Alzheimer’s Disease Subjects: Study Update.
Alzheimer s & Dementia·2022
The PIONEER Study: A multi‐center, randomized, double‐blind, placebo‐controlled phase 2 trial of the effects of T3D‐959 on safety, cognition, function and plasma biomarkers in mild to moderate Alzheimer’s disease subjects: Rationale and study design
Alzheimer s & Dementia·2020· 3 citedOpen Access
An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer’s Disease
Journal of Alzheimer s Disease·2019· 48 citedOpen Access
Abstracts of 20th Annual ASENT Meeting
Neurotherapeutics·2018· 2 citedOpen Access
O1‐12‐04: EFFECTS OF A PPAR DELTA/GAMMA AGONIST, T3D‐959, ON METABOLIC AND COGNITIVE FUNCTIONS IN MILD TO MODERATE ALZHEIMER'S DISEASE SUBJECTS
Alzheimer s & Dementia·2018
Intraoperative Magnesium Administration Does Not Improve Neurocognitive Function After Cardiac Surgery
Stroke·2013· 77 citedOpen Access
Inhibition of Protein Misfolding/Aggregation Using Polyglutamine Binding Peptide QBP1 as a Therapy for the Polyglutamine Diseases
Neurotherapeutics·2013· 36 citedOpen Access
Bathing the brain
Journal of Clinical Investigation·2013· 34 citedOpen Access
Alzheimer’s disease: the new promise
Journal of Clinical Investigation·2012· 10 citedOpen Access
Old Drug, New Hope for Alzheimer's Disease
Science·2012· 43 cited
The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases
Journal of Amino Acids·2011· 29 citedOpen Access
Genome-Wide Scan of Copy Number Variation in Late-Onset Alzheimer's Disease
Journal of Alzheimer s Disease·2010· 127 citedOpen Access
Correction: A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia
PLoS Genetics·2009· 20 citedOpen Access
A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia
PLoS Genetics·2009· 445 citedOpen Access
Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia
Leukemia·2008· 15 cited
Identification of Chemical Inhibitors to Human Tissue Transglutaminase by Screening Existing Drug Libraries
Chemistry & Biology·2008· 67 citedOpen Access
Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.
Blood·2007· 2 cited
Optimization of a Polyglutamine Aggregation Inhibitor Peptide (QBP1) Using a Thioflavin T Fluorescence Assay
Assay and Drug Development Technologies·2007· 12 cited
page 1 of 7Next →

Frequent Co-authors

Allen D. Roses(19), Ann M. Saunders(17), James R. Burke(10), D. E. Schmechel(8), Jeffery M. Vance(6), Elizabeth H. Corder(5), Dmitry Goldgaber(5), Karl H. Weisgraber(5), Donald E. Schmechel(5), Fusao Hirata(5), Margaret A. Pericak‐Vance(4), Julius Axelrod(4), Mark F. Newman(4), William D. White(4), Jan J. Enghild(3), Christine Hulette(3), Ken Schmader(3), Michel Goedert(3), Ross Jakes(3), Karl H. Weisgraber(3)